Originally published June 17. This article has been corrected from a previous version to reflect that Myriad is developing the HRD test to guide platinum-based treatment decisions, and does not plan to launch BRACAnalysis in this setting.

NEW YORK (GenomeWeb) – This fall Myriad Genetics is planning to launch BRACAnalysis as a companion test that can pick out which breast cancer patients have BRCA1 and BRCA2 mutations, and therefore will respond to the PARP inhibitor olaparib.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.